Follicular Lymphoma

This is a common type of lymphoma that starts in the B-cells of the lymph nodes. It tends to grow slowly and often affects multiple lymph nodes. It's named after the way the cancer cells group together in clusters, like the follicles in an onion.

Condition

What people with Follicular Lymphoma report

Every report comes from a Lived member, sent anonymously.

Have you tried Rituximab for Follicular Lymphoma?

NameHow it went

About Follicular Lymphoma

What It Is

Follicular lymphoma is a usually slow-growing cancer of B cells, the white blood cells that normally make antibodies. It is a type of non-Hodgkin lymphoma. It starts in the lymph nodes, where the cancer cells grow in rounded clusters that resemble the follicles in which healthy B cells mature, which is where the name comes from. About 1 in 5 lymphomas in the United States is follicular lymphoma. The average age at diagnosis is around 60, and it is rare in young people. The most common sign is painless swelling of lymph nodes, often in several areas at once, such as the neck, armpit or groin. The lymphoma often also involves the bone marrow and sometimes the spleen, yet many people feel well when it is found. Fevers, drenching night sweats and unexplained weight loss are less common, and when they appear they can signal growth or a change into a faster-growing form. Follicular lymphoma usually responds well to treatment, but in most people it is hard to cure and tends to come back over the years. That slow, recurring pattern shapes how it is managed: some people are watched rather than treated at first, and care is usually long-term rather than a single course of therapy.

Causes & Risk Factors

Researchers do not know exactly why follicular lymphoma develops. In most cases the lymphoma cells carry a characteristic genetic change in which pieces of chromosomes 14 and 18 swap places, rearranging a gene called BCL2 so that the cells make too much of a protein that keeps them alive longer than they should live. This change is found in the lymphoma cells themselves, and further genetic changes build up in those cells as the disease progresses. The known risk factors come from studies of non-Hodgkin lymphoma as a group. Risk rises with age, and having a parent, sibling or child with non-Hodgkin lymphoma increases it. A weakened immune system, for example after an organ transplant or with HIV, also raises risk. Some studies have linked benzene and certain weed and insect killers, and possibly excess body weight, to a higher risk, but these links are still being studied. None of these factors explains why a particular person developed the disease.

How It's Diagnosed

Swollen lymph nodes are much more often caused by infection than by lymphoma, so testing usually starts when a node stays enlarged without a clear explanation. The diagnosis requires a biopsy. Removing a whole lymph node, or a substantial piece of one, is preferred over a needle sample when it can be done safely, because the pathologist needs enough tissue to see the clustered growth pattern, confirm the cell type with special stains and check whether any area has become more aggressive. A test for the BCL2 rearrangement can support the diagnosis when the picture is unclear. The pathologist also notes how many large cells are present. Older reports use grades 1, 2, 3A and 3B. Grades 1 to 3A behave similarly and are now often grouped as classic follicular lymphoma. Grade 3B, now called follicular large B-cell lymphoma, behaves like diffuse large B-cell lymphoma, a fast-growing type, and is treated the way that disease is. Staging then shows how far the lymphoma extends. A PET-CT scan, which combines a CT scan with an image of where the lymphoma is metabolically active, is the standard imaging test. Blood tests check blood counts and markers such as lactate dehydrogenase (LDH) and beta-2 microglobulin that help estimate outlook, and screen for hepatitis B, hepatitis C and HIV, which affect treatment safety. A bone marrow biopsy is recommended when the scan suggests limited disease, to confirm it before radiation, and is otherwise done only when blood counts or other findings call for it. Stages I and II describe lymphoma confined to one area or nearby areas; stages III and IV describe more widespread disease, which is how most people are diagnosed. Doctors may calculate a score such as the Follicular Lymphoma International Prognostic Index (FLIPI), based on age, stage, number of involved node areas and blood results. It describes outlook for groups of patients but is not usually used to choose treatment.

Treatment Options

Treatment depends on the stage, how much lymphoma there is, whether it is causing symptoms or affecting organs, and a person's age, other health conditions and preferences. About 1 in 10 people are diagnosed with limited, early-stage disease. For them, radiation therapy aimed at the affected lymph nodes is the usual treatment and offers a chance of cure. Rituximab, an antibody medicine, may be added, or used on its own when radiation is not a good fit. For widespread lymphoma that is small in amount and not causing problems, watchful waiting (also called active surveillance) is a standard choice. It means regular checkups and blood tests, with treatment starting if the lymphoma causes symptoms, threatens an organ or grows substantially. Starting treatment early in this situation has not helped people live longer and brings side effects sooner. Half of people on watchful waiting need treatment within about three years, and some never do. A short course of rituximab alone is another accepted option; it delays growth of the lymphoma but has not been shown to improve survival. When there is more lymphoma or it is causing symptoms, the usual treatment combines chemotherapy with an antibody that targets CD20, a protein on the surface of B cells. Rituximab (Rituxan, also available as biosimilar versions) is the standard choice. Obinutuzumab (Gazyva) is an alternative that kept lymphoma controlled longer in a large trial, at the cost of more side effects and without longer survival. The chemotherapy partner is often bendamustine, which tends to cause fewer mouth sores and fewer drops in neutrophils (the white cells that fight bacteria) and does not cause hair loss, or a combination called CHOP (several chemotherapy drugs given with a steroid), which is preferred if the lymphoma is behaving aggressively. For people who respond, continuing the antibody every two months for two years (maintenance) lengthens the time before the lymphoma returns. These treatments lower the body's defenses. Before an anti-CD20 antibody, people are tested for hepatitis B because the medicine can reactivate the virus, and those who carry it are given antiviral medicine. Bendamustine also lowers other immune cells for months, so doctors may recommend preventive antibiotics after it, along with keeping vaccinations up to date. When the lymphoma comes back, it often responds again. Options include another antibody-based treatment; lenalidomide (Revlimid), a capsule related to thalidomide that is combined with rituximab and must not be used during pregnancy; bispecific antibodies such as mosunetuzumab (Lunsumio), which bring the body's own T cells into contact with lymphoma cells; and CAR T-cell therapy, in which a person's T cells are modified in a lab to attack the lymphoma. Bispecific antibodies and CAR T-cell therapy can trigger cytokine release syndrome, an immune reaction with fever, chills and low blood pressure, and CAR T cells can also cause confusion or other nervous system effects, so they start with close monitoring. A stem cell transplant is considered for selected people. Clinical trials are an option at many points.

What to Expect

Follicular lymphoma is usually a long-term condition with periods of response and relapse. Most people respond well to treatment, sometimes with no detectable lymphoma for years, but it commonly returns and may need several rounds of treatment over a lifetime. Between treatments, many people keep up their usual work and activities, with periodic checkups and blood tests. Routine scans are often not needed once the lymphoma is in remission, because finding a relapse on a scheduled scan has not been shown to improve survival compared with finding it through symptoms or examination. The outlook has improved substantially. Current European guidelines estimate that the median survival for people diagnosed today likely exceeds 20 years, meaning about half are expected to live longer than that. This is a group average rather than a personal forecast, and age, overall health and the extent of the lymphoma all shift an individual's outlook. How well the first treatment works is one of the clearest signals of the road ahead: about 15 to 20 percent of people treated with rituximab and chemotherapy do not respond or relapse within two years of starting treatment, and that group tends to have a harder course and often benefits from a lymphoma specialist's input. Over time, follicular lymphoma can change into a fast-growing lymphoma, most often diffuse large B-cell lymphoma, usually several years after diagnosis. This is called transformation. It is confirmed with a new biopsy and treated promptly, generally as diffuse large B-cell lymphoma is. Agreeing with the care team on the follow-up schedule, and on which changes would lead to treatment, makes the long periods between treatments easier to navigate.

When to Seek Help

See a doctor about a lump or swollen lymph node that does not go away, especially without an obvious infection, or about persistent unexplained tiredness. If you have follicular lymphoma, contact your care team promptly about a lymph node that suddenly grows quickly or new fevers, drenching night sweats or unintended weight loss, since these can signal transformation, which needs treatment right away. During treatment, call your care team right away for a temperature of 100.5°F (38°C) or higher, chills or other signs of infection, because infections during cancer treatment can become life threatening.

Questions to Ask Your Doctor

  1. 1.Is my lymphoma limited or widespread, and does it need treatment now or can we safely watch it?
  2. 2.If we choose watchful waiting, how often will I be checked, and which changes would lead us to start treatment?
  3. 3.What can the treatment you recommend realistically achieve, and what side effects and infection precautions come with it?
  4. 4.What signs would make you suspect transformation, and what should I report between visits?
  5. 5.Would a lymphoma specialist's opinion or a clinical trial be worth considering for me?

Last reviewed • Oct 2026

Educational content, not medical advice.